COMPOSITIONS COMPRISING N,N-DIMETHYLTRYPTAMINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES AND USES THEREOF

1 . A pharmaceutical composition comprising N,N-dimethyltryptamine, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier and/or excipient.

2 . The pharmaceutical composition of claim 1 , wherein the composition is a unit dosage from composition.

3 . The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is a solid unit dosage form composition.

4 . The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is a liquid unit dosage form composition.

5 . The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is packaged as a single unit dose or as a plurality of single unit doses.

6 . The pharmaceutical composition of claim 2 , wherein the unit dosage form comprises from 30 mg to 130 mg of N,N-dimethyltryptamine.

7 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration or intravenous administration.

8 . A method of treating cerebral ischemia, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising N,N-dimethyltryptamine, or a pharmaceutically acceptable salt thereof.

9 . A method of treating hypoxia, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising N,N-dimethyltryptamine, or a pharmaceutically acceptable salt thereof.

10 . The method of claim 8 or 9 , wherein the pharmaceutical composition further comprises at least on pharmaceutically acceptable carrier and/or excipient.

11 . The method of claim 8 or 9 , wherein the pharmaceutical composition is a free-flowing powder, a tablet, a capsule, a lozenge, a liquid, a liquid concentrate, or a syrup.

12 . The method of claim 8 or 9 , wherein the pharmaceutical composition is a unit dosage form composition.

13 . The method of claim 8 or 9 , wherein an amount of N, N-dimethyltryptamine in the unit dosage form ranges from about 30 mg to about 130 mg.

14 . The method of claim 8 or 9 , wherein the amount of N,N-Dimethyltryptamine is about 1 mg, about 2.5 mg, about 5 mg, or about 10 mg.

15 . The method of claim 8 or 9 , wherein the pharmaceutical composition is administered orally or intravenously.

16 . A pharmaceutical composition comprising N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier and/or excipient.

17 . The pharmaceutical composition of claim 16 , wherein the composition is a unit dosage from composition.

18 . The pharmaceutical composition of claim 17 , wherein the pharmaceutical composition is a solid unit dosage form composition.

19 . The pharmaceutical composition of claim 17 , wherein the pharmaceutical composition is a liquid unit dosage form composition.

20 . The pharmaceutical composition of claim 17 , wherein the pharmaceutical composition is packaged as a single unit dose or as a plurality of single unit doses.

21 . The pharmaceutical composition of claim 17 , wherein the unit dosage form comprises from 30 mg to 130 mg of N,N-dimethyltryptamine.

22 . The pharmaceutical composition of claim 16 , wherein the pharmaceutical composition is formulated for oral administration.

23 . A method of treating cerebral ischemia, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising N,N-dimethyltryptamine, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.

24 . A method of treating hypoxia, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising N,N-dimethyltryptamine, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.

25 . The method of claim 23 or 24 , wherein said the pharmaceutical composition further comprises at least on pharmaceutically acceptable carrier and/or excipient.

26 . The method of claim 23 or 24 , wherein the pharmaceutical composition is a free-flowing powder, a tablet, a capsule, a lozenge, a liquid, a liquid concentrate, or a syrup.

27 . The method of claim 23 or 24 , wherein the pharmaceutical composition is a unit dosage form composition.

28 . The method of claim 23 or 24 , wherein an amount of N,N-dimethyltryptamine in the unit dosage form ranges from about 30 mg to about 130 mg.

29 . The method of claim 23 or 24 , wherein the amount of N,N-dimethyltryptamine is about 1 mg, about 2.5 mg, about 5 mg, or about 10 mg.

30 . The method of claim 23 or 24 , wherein the pharmaceutical composition is administered orally or intravenously.

31 . The pharmaceutical composition of any preceding claim , wherein the N-acylethanolamine is selected from the group consisting of N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), salts thereof and any combination thereof.

32 . The method of any preceding claim , wherein the N-acylethanolamine is selected from the group consisting of N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), salts thereof and any combination thereof.

33 . The pharmaceutical composition of any preceding claim , wherein the N-acylethanolamine is PEA or a pharmaceutically acceptable salt thereof.

34 . The method of any preceding claim , wherein the N-acylethanolamine is PEA or a pharmaceutically acceptable salt thereof.